Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allogene Therapeutics Inc.

1.42
-0.0300-2.07%
Post-market: 1.40-0.0199-1.40%18:02 EDT
Volume:2.18M
Turnover:3.12M
Market Cap:308.52M
PE:-1.07
High:1.49
Open:1.41
Low:1.39
Close:1.45
Loading ...

Allogene Therapeutics Q4 EPS $(0.28) Beats $(0.33) Estimate

Benzinga
·
14 Mar

Allogene to invest $37.3M in expanded MRD assay pact with Foresight Diagnostics

TIPRANKS
·
26 Feb

Allogene Therapeutics Inc - Expanded Collaboration to Develop Mrd Assay in EU, UK, Canada, Australia

THOMSON REUTERS
·
26 Feb

Allogene Therapeutics Inc - on Feb 19. Amended Strategic Collaboration Agreement With Foresight Diagnostics

THOMSON REUTERS
·
26 Feb

Allogene Therapeutics Inc: Expands Strategic Partnership With Foresight Diagnostics

THOMSON REUTERS
·
26 Feb

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

GlobeNewswire
·
26 Feb

Baird ‘encouraged’ by Allogene CAR-T therapy update

TIPRANKS
·
19 Feb

Allogene Therapeutics Up Nearly 42%, on Pace for Record Percent Increase -- Data Talk

Dow Jones
·
15 Feb

William Blair Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)

TIPRANKS
·
14 Feb

BRIEF-Allogene Therapeutics Announces Publication Of Durable Response Data From Phase 1 Alpha/Alpha2 Trials Of The Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501

Reuters
·
14 Feb

Allogene publishes data from ALPHA, ALPHA2 trials of cemacabtagene ansegedleucel

TIPRANKS
·
14 Feb

Allogene Therapeutics Announces Publication of Durable Response Data From Phase 1 Alpha/Alpha2 Trials of the Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

THOMSON REUTERS
·
14 Feb

Allogene Therapeutics Inc - Cema-Cel Achieves Orr of 58% and Cr of 42% in Study

THOMSON REUTERS
·
14 Feb

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

GlobeNewswire
·
14 Feb

Allogene Therapeutics Announces Participation in February Investor Conferences

GlobeNewswire
·
04 Feb

FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases

Zacks
·
30 Jan

Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer

THOMSON REUTERS
·
29 Jan

Press Release: Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer

Dow Jones
·
29 Jan

Canaccord Genuity Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)

TIPRANKS
·
29 Jan

Allogene Therapeutics Cleared to Start Phase 1 Testing of ALLO-329 Drug Candidate

MT Newswires Live
·
28 Jan